SP600125
Description
MAPK/JNK inhibitor.
A novel and selective inhibitor of c-Jun N-terminal kinase (JNK) SP600125 is an anthrapyrazolone inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-Jun. It prevents the activation of inflammatory genes such as COX-2, IL-2 IFN-γ and TNF-α.8,9 It prevents the activation of JNK after brain ischemia and may be effective in treatment of ischemic stroke.10
- Sigma Description
Genes Affected
Suppliers
Usage Notes
References
- Cizelsky et al., 2014
- Zhang et al., 2013
- Bayliss et al., 2012
- Suzuki et al., 2007
- Ding et al., 2013
- Cha et al., 2008
- Fuentealba et al., 2007
- Cheng et al., 2012
- Choi et al., 2010
- Dickinson et al., 2009
- Li et al., 2008
- Tonge et al., 2008
- Mortensen et al., 2008
- Paek et al., 2010
- Kalin et al., 2009
- Sapkota et al., 2007
- Zacchigna et al., 2006
- Mohney et al., 2003
- Sugiura et al., 2009
- Maurus et al., 2005
- Kusakabe et al., 3071
- Garriock et al., 2005
- Liao et al., 2006
- Du Pasquier et al., 2011
- Hasegawa et al., 2004
- Goss et al., 2001
- Bein et al., 2004
- Hutchins et al., 2013
- Dush et al., 2013
- Luu et al., 2015
>28 Xenbase articles contain a reference to SP600125 according to textpresso